Biotech-Start-up G.ST Antivirals starts first clinical trial
New therapeutic approach against rhinovirus infections
Wien (OTS) - Less than three years after its foundation, the start-up G.ST Antivirals reaches a major milestone in the development of its lead asset and begins clinical phase I at the Vienna General Hospital. G.ST Antivirals is testing a nasal spray, which was developed specifically for use against colds and other upper respiratory tract infections.
Based on years of research into metabolic changes in infected cells, the new nasal spray is designed to!-->!-->!-->…